Vol. 5 No. 2 (2025): February
Reimbursement Reviews

Eplontersen (Wainua)

decorative image of the issue cover

Published February 18, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses eplontersen, 56 mg/mL, 45 mg single-dose prefilled pen for SC injection.
  • Indication: For the treatment of polyneuropathy associated with stage 1 or stage 2 hereditary transthyretin-mediated amyloidosis in adults.